coleneuramide
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00307749)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
inhibitor - CRMP-5
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@]1(C(=O)N[C@@H]2CC[C@@]3(C)[C@@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]43)C2)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1- Mol. weight
- 692.98 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105634 ↗
Also known as
- coleneuramide
- coleneuramide
- mcc-257
- mcc-257
- mcc-257
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00307749 | Phase 2 | Mar 1, 2006 | Mitsubishi, Mitsubishi Tanabe |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi | For profit | 1 | 0 | 1 | 2006 |
| Mitsubishi Tanabe | For profit | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1